Atopic Dermatitis

A group of dermatologists and dermatology students studied why AD may be related to certain cardiovascular diseases, neuropsychiatric diseases, autoimmune diseases, and obesity.

To date, publications about health care disparities in atopic dermatitis in Latin American countries are few and far between.

Investigators compared these outcomes due to limited research in the space, with previous surveys suggesting care disparities.

Researchers link proximity to heavy traffic and risk of atopic dermatitis in new study.

Patients suffering from atopic dermatitis may suffer more during the cold, dry winter month. Bernard Cohen, MD, professor of pediatrics and dermatology at Johns Hopkins University School of Medicine in Baltimore, Maryland, explores various treatment options that will add moisture back into the skin during seasonal flare-ups.

Adolescents and adults with seborrheic dermatitis may have a new topical treatment soon.

Research published in JAMA Dermatology finds dupilumab works quickly and safely for patients with erythrodermic atopic dermatitis.

Alexis shares take-home points from his popular sessions at South Beach Symposium.

Andrew F. Alexis, MD, MPH, and Benjamin N. Lockshin, MD, talk about how clinical approaches and understanding of risk/benefit profiles are evolving in light of the emerging long-term data.

Andrew F. Alexis, MD, MPH, and Benjamin N. Lockshin, MD, review the impact of the open-label extension data on the current atopic dermatitis landscape.

Matt Zirwas, MD, shares tips on diagnosing various forms of hand dermatitis and what patients can do to relieve symptoms of dermatitis at Maui Derm Hawaii 2023.

Thought leaders discuss the importance of rapid onset of action in atopic dermatitis care amid the backdrop of compelling 4-year efficacy and safety data for dupilumab.

Continuing their discussion about efficacy, Andrew F. Alexis, MD, MPH, and Benjamin N. Lockshin, MD, review long-term results on pruritus. Additionally, they explore data for patients who switched from weekly to every-other-week dupilumab treatment.

Brett King, M.D, Ph.D and Alexandra Golant, M.D summarize their thoughts on optimizing treatment outcomes for patients suffering from atopic dermatitis with the JAK inhibitor class.

Experts in atopic disease management review the efficacy and safety data of the JAK inhibitor class, highlighting the importance of time to treatment response and itch reduction.

Drs Alexandra Golant and Brett King discuss the role that atopic disease severity and treatment resistance play in the selection of oral vs systemic treatment for their patients.

Brett King, M.D, Ph.D and Alexandra Golant M.D comment on their considerations on the management of patients suffering from atopic dermatitis, highlighting the importance of body surface area and patient preference in treatment selection.

Andrew F. Alexis, MD, MPH, and Benjamin N. Lockshin, MD, discuss the relevance of the 4-year efficacy data for dupilumab in adults with moderate to severe atopic dermatitis, with a focus on IGA and EASI scores.

Continuing their discussion about safety, Andrew F. Alexis, MD, MPH, and Benjamin N. Lockshin, MD, take a closer look at conjunctivitis data from the long-term use of dupilumab

Andrew F. Alexis, MD, MPH, and Benjamin N. Lockshin, MD, review the design of the LIBERTY-AD open-label extension trial and share clinical context regarding safety findings.

Thought leaders share strategies for talking to patients about the importance of treatment adherence in the long-term management of atopic dermatitis.

Recommendations were made for patients to help relieve inflammation, itching and infections.

JAK inhibitors may cause less adverse events compared with traditional systemic therapies.

In part 5 of this Frontline Forum, Raj Chovatiya, MD, PhD; Neal D. Bhatia, MD; Alexandra K. Golant, MD; and Brett King, MD, PhD, discuss the rapidly changing use for JAK inhibitors and other agents for atopic dermatitis.

Andrew F. Alexis, MD, MPH, and Benjamin N. Lockshin, MD, evaluate the effect of the rapidly changing therapeutic landscape in atopic dermatitis.

Results from the test reveal that high levels of the immune biomarker Thymus and Activation-Regulated Chemokine (TARC) in babies increases their chances of developing atopic dermatitis.

Andrew F. Alexis, MD, MPH, and Benjamin N. Lockshin, MD, review the burden of atopic dermatitis and discuss how they talk to patients about the impact their disease has on their lives.

In part 4 of this Frontline Forum, Raj Chovatiya, MD, PhD; Neal D. Bhatia, MD; Alexandra K. Golant, MD; and Brett King, MD, PhD, discuss the rapidly changing use for JAK inhibitors and other agents for atopic dermatitis.

In part 3 of this Frontline Forum, Raj Chovatiya, MD, PhD; Neal D. Bhatia, MD; Alexandra K. Golant, MD; and Brett King, MD, PhD, discuss the rapidly changing use for JAK inhibitors and other agents for atopic dermatitis.

In part 2 of this Frontline Forum, Raj Chovatiya, MD, PhD; Neal D. Bhatia, MD; Alexandra K. Golant, MD; and Brett King, MD, PhD, discuss the rapidly changing use for JAK inhibitors and other agents for atopic dermatitis.